Avanos Medical (AVNS) Q3 2024: Digestive Health Grows 6% as Transformation Offsets Pain Portfolio Setbacks
Digestive health strength and cost discipline offset pain management headwinds for Avanos in Q3, as the company’s ongoing transformation and portfolio optimization provided margin stability despite operational setbacks in surgical pain. Leadership transition and product innovation signal a focus on sustainable, above-market growth, but execution risk remains as Avanos navigates reimbursement uncertainty and soft spots in key product lines. Investors should watch for clarity at January’s JPMorgan conference, where 2025 growth guidance and strategic updates will be unveiled.
Summary
- Digestive Health Outperformance: Core feeding solutions continued to gain share and drive steady growth.
- Pain Management Drag: Surgical pain and North America Cool Leaf softness weighed on topline momentum.
- Transformation Progress: Portfolio focus and SG&A discipline underpinned margin gains despite mixed revenue trends.
Business Overview
Avanos Medical is a medical device company specializing in digestive health and pain management solutions. The business is organized around two major segments: Digestive Health (enteral feeding and neonatal products) and Pain Management & Recovery (surgical pain, IVP, Game Ready, and HA portfolios). Avanos generates revenue by selling proprietary devices and consumables to hospitals, ambulatory surgical centers (ASCs), and international markets, with a focus on recurring product sales and innovation-driven market share gains.
Performance Analysis
Q3 results reflected Avanos’ ongoing transformation, as the company delivered modest organic growth despite operational headwinds in pain management. Digestive health was the clear outperformer, posting nearly 6% organic growth and reinforcing Avanos’ leadership in long-term and neonatal feeding. This segment benefited from continued NFIT conversion demand and share gains from a competitor’s backorder, though management cautioned that the NFIT tailwind is entering its later innings.
The pain management and recovery portfolio saw mixed results. While the Ambit product line and IVP business delivered strong double-digit growth, surgical pain—particularly the OnQ line—faced supply chain disruptions and customer turnover, resulting in missed procedures and lost sales. North America Cool Leaf also underperformed, though international Cool Leaf sales were buoyed by reimbursement tailwinds. Notably, the Game Ready portfolio continued its double-digit growth streak, but faces tougher comps in Q4. Margin expansion was supported by SG&A optimization (down 180 basis points YoY) and a favorable customs duty refund, partially offsetting inflation and price pressure in HA. Free cash flow and balance sheet strength provide strategic flexibility for M&A and share repurchases.
- Digestive Health Resilience: Consistent above-market growth, with Neomed and legacy enteral feeding driving results.
- Surgical Pain Volatility: OnQ supply issues and customer churn dampened segment performance, with recovery dependent on reimbursement clarity.
- Margin Expansion: SG&A savings and operational transformation offset gross margin pressure from product mix and inflation.
While transformation initiatives are delivering financial and operational improvements, inconsistent topline growth in pain management and pockets of execution risk remain key watchpoints heading into 2025.
Executive Commentary
"Although we are pleased with our transformation progress, we fell short in the third quarter of our stated objective of mid-single-digit organic growth, which also negatively impacted gross margin for the quarter. Our paying portfolio, particularly surgical pain, was the primary driver of this underperformance, partially offset by another strong quarter in digestive health."
Michael Greiner, Interim CEO
"Margin expansion was positively impacted by continued SG&A optimization efforts and a favorable outcome from a Canadian customs duty refund matter. Adjusted SG&A as a percentage of revenue was 39.8%, marking an improvement of 180 basis points compared to the third quarter of last year and 320 basis points sequentially."
Michael Greiner, Interim CEO
Strategic Positioning
1. Portfolio Optimization and Transformation Discipline
Avanos’ transformation plan has centered on focusing resources on higher-margin, market-leading categories, as evidenced by the divestiture of the respiratory health business and targeted product exits. This portfolio reshaping aligns capital and commercial efforts with segments where Avanos can win, supporting margin and ROIC improvement.
2. Digestive Health as the Growth Anchor
Digestive health remains the company’s most reliable growth engine, with both legacy enteral feeding and Neomed neonatal products driving above-market expansion. Product innovation (e.g., CoreGrip SR Nasal Bridal System FDA approval) and continued share gains are expected to sustain outperformance, though the NFIT conversion cycle is maturing.
3. Pain Management: Execution and Reimbursement Levers
Pain management performance is increasingly tied to operational execution and reimbursement dynamics. The OnQ line’s Q3 setback was attributed to supply chain disruptions and customer churn, but management sees upside from the No Pain Act, pending clarity on reimbursement rates. Ambit’s growth in the ASC channel and IVP’s double-digit performance highlight the potential for segment recovery if execution stabilizes.
4. Cost Management and Cash Flow Focus
SG&A optimization and plant-level transformation initiatives are yielding tangible margin benefits, with cost discipline helping to offset inflation and price pressure. Free cash flow generation and a strong balance sheet position Avanos to pursue strategic M&A and opportunistic share buybacks without compromising leverage targets.
5. Leadership Transition and Strategic Continuity
With Michael Greiner stepping in as interim CEO, Avanos is maintaining continuity in its transformation agenda. The board’s ongoing CEO search and reappointment of experienced executives signal a commitment to stability and strategic follow-through during this pivotal phase.
Key Considerations
This quarter’s results underscore both the progress and the remaining hurdles in Avanos’ transformation journey. The company’s ability to sustain margin gains and capitalize on its digestive health franchise will be critical as it addresses pain management volatility and prepares for reimbursement-driven shifts in 2025.
Key Considerations:
- Digestive Health Share Gains: Continued leadership and innovation underpin above-market growth, but NFIT conversion tailwind is maturing.
- Pain Management Uncertainty: OnQ and Cool Leaf require operational recovery and reimbursement clarity to resume growth.
- Transformation Execution: Portfolio focus and cost discipline are delivering margin and cash flow improvement, but topline inconsistency persists.
- Leadership Transition: Interim CEO and CFO appointments maintain momentum, but permanent leadership decisions remain outstanding.
- Capital Deployment Flexibility: Strong cash flow and low leverage enable M&A and share repurchase opportunities to support shareholder value.
Risks
Execution risk remains elevated in pain management, with OnQ supply chain recovery and customer re-engagement crucial for segment stabilization. Digestive health growth may moderate as NFIT adoption plateaus, and pricing pressure in HA could offset volume gains. Reimbursement uncertainty (especially from the No Pain Act) introduces further volatility, and leadership transition adds organizational risk if strategic continuity falters.
Forward Outlook
For Q4, Avanos guided to:
- Revenue of $175 million to $180 million, targeting low to mid-single-digit organic growth
- Adjusted gross margin of approximately 59%
- Adjusted SG&A around 40% of revenue
- Adjusted diluted EPS between $0.38 and $0.43
For full-year 2024, management maintained its transformation focus and highlighted:
- Sustained above-market digestive health growth, driven by product innovation and share gains
- Operational recovery and reimbursement developments in pain management as key watchpoints
Management will provide a comprehensive 2025 outlook and strategic update at the JPMorgan conference in January, with particular attention on reimbursement impacts, growth targets, and transformation milestones.
Takeaways
Avanos’ Q3 highlights the benefits and challenges of focused transformation, as margin and cash flow gains are offset by uneven topline execution. Digestive health remains a core strength, while pain management’s recovery hinges on supply chain fixes and reimbursement clarity.
- Digestive Health Drives Stability: Market share gains and product launches support growth, but tailwinds may fade as adoption cycles mature.
- Pain Management Needs Rebound: OnQ and Cool Leaf require operational fixes and reimbursement tailwinds to return to growth.
- Transformation and Capital Flexibility: Margin discipline and a strong balance sheet position Avanos for opportunistic investment and shareholder returns, but execution risk remains a key investor focus for 2025.
Conclusion
Avanos’ transformation is yielding tangible financial benefits, but the company’s growth narrative is now dependent on operational recovery in pain management and continued innovation in digestive health. Investors should monitor the upcoming strategic update in January for clarity on growth targets and risk mitigation as Avanos enters the next phase of its transformation journey.
Industry Read-Through
Avanos’ Q3 results underscore key themes for the broader medical device sector: Portfolio focus and divestitures are driving margin and ROIC improvement, but execution risk in specialty product lines remains high. Digestive health market share gains and product innovation are critical for sustaining above-market growth, though adoption cycles can create volatility. Reimbursement policy changes (such as the No Pain Act) are likely to reshape pain management economics, with implications for both incumbents and new entrants. Cost discipline and capital allocation flexibility are emerging as differentiators for medtech companies navigating mixed demand and operational headwinds.